GERN Stock Trend Given the current short-term trend, the stock is expected to fall -6.76% during the next 3 months and, with a 90% probability hold a price between $1.09 and $1.69 at the end of this 3-month period.
What are analysts' target prices for Geron's (Gern) stock?
5 equities research analysts have issued twelve-month target prices for Geron's stock. Their predictions range from $3.00 to $4.50. On average, they expect Geron's stock price to reach $3.90 in the next year.
Where can I buy Geron shares?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Geron's stock price today?
How has coronavirus affected Geron's stock?
Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN shares have increased by 39.8% and is now trading at $1.44. View which stocks have been most impacted by COVID-19.
What does Gern stand for?
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financia...
What is the price forecast for GERN?
The 4 analysts offering 12-month price forecasts for Geron Corp have a median target of 3.50, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +87.17% increase from the last price of 1.87.
Is GERN stock a good buy?
The financial health and growth prospects of GERN, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Will GERN stock recover?
The Wall Street analyst predicted that Geron's share price could reach $4.00 by Nov 2, 2022. The average Geron stock price prediction forecasts a potential upside of 131.21% from the current GERN share price of $1.73.
Should I sell Geron?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock.
What is Geron's consensus rating and price target?
According to the issued ratings of 4 analysts in the last year, the consensus rating for Geron stock is Buy based on the current 4 buy ratings for...
Do Wall Street analysts like Geron more than its competitors?
Analysts like Geron stock more than the stock of other Medical companies. The consensus rating score for Geron is 3.00 while the average consensus...
Do MarketBeat users like Geron more than its competitors?
MarketBeat users like Geron stock more than the stock of other Medical companies. 69.55% of MarketBeat users gave Geron an outperform vote while me...
Does Geron's stock price have much upside?
According to analysts, Geron's stock has a predicted upside of 300.73% based on their 12-month price targets.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
GERN's average price target has moved up $0.5 over the prior 30 weeks.
The Trend in the Broker Recommendations
Over the past 20 months, GERN's average broker recommendation rating improved by 0.
How much of Geron stock is held by insiders?
Only 5.90% of the stock of Geron is held by insiders.
What is the average rating of Geron?
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
What is Geron Corp?
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
What is the gern symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
What is the P/E ratio of Geron?
The P/E ratio of Geron is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Geron pay dividends?
Geron does not currently pay a dividend.
About Geron Corporation
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Stock Podcast
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
When will Geron release its financial results?
MENLO PARK, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, Ma...
What is Geron Corporation?
FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies...
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Stock Price Forecast
The 5 analysts offering 12-month price forecasts for Geron Corp have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 3.00. The median estimate represents a +284.62% increase from the last price of 1.04.
Analyst Recommendations
The current consensus among 5 polled investment analysts is to Buy stock in Geron Corp. This rating has held steady since November, when it was unchanged from a Buy rating. Move your mouse over past months for detail
GERN earnings per share forecast
What is GERN 's earnings per share in the next 3 years based on estimates from 3 analyst s?
GERN revenue forecast
What is GERN 's revenue in the next 3 years based on estimates from 2 analyst s?
GERN revenue growth forecast
How is GERN forecast to perform vs Biotechnology companies and vs the US market?
Release
Risks
- 4 brokers have issued 12 month target prices for Geron's shares. Their predictions range from $1.80 to $4.00. On average, they anticipate Geron's share price to reach $3.0125 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price. View Analyst Price Targets for Geron.
Ratings
- 4 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Geron in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Geron.
Reception
- News coverage about GERN stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gero…
Ownership
- Geron saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 42,790,023 shares, an increase of 0.6% from the March 29th total of 43,065,652 shares. Based on an average trading volume of 4,045,055 shares, the short-interest ratio is presently 10.6 days. Currently, 23.1% of the shares of the stock are sold short. View Geron's Curr…
Business
- Geron has a market capitalization of $324.54 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.
Location
- Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected].